

Atty. Dkt. No. 074066-0115

Listing of Claims

The following list is complete and supercedes previous claims in the case. After this amendment, claims 1-6, and 36-57, and 59-68 are pending in the application.

1. (Original) A preservation solution for cells, tissues, and organs comprising a combination of polyglycerol and lactose in an amount effective to preserve the cells, tissues, and organs under hypothermic conditions.

2. (Currently amended) The preservation solution of claim 1 wherein the lactose is comprises alpha-lactose.

3. (Original) The preservation solution of claim 1 wherein the polyglycerol is from $n = 2$ to $n = 200$ monomers.

4. (Original) The preservation solution of claim 1 wherein the polyglycerol is decaglycerol or hexaglycerol.

5. (Original) The preservation solution of claim 1 wherein the lactose is at a concentration from 11 mM to 250 mM.

6. (Original) The preservation solution of claim 1 wherein the polyglycerol is at a concentration of 10 mOsm to 250 mOsm.

7-35 (Cancelled)

36. (Previously presented) The preservation solution of claim 1 further comprising glutathione.

37. (Previously presented) The solution of claim 36, further comprising chondroitin sulfate.

38. (Previously presented) The solution of claim 37 wherein the chondroitin sulfate is chondroitin sulfate A.

Atty. Dkt. No. 074066-0115

39. (Previously presented) The solution of claim 37, wherein the concentration of chondroitin sulfate is on the order of 0.01% w/v to 1% w/v.

40. (Previously presented) The solution of claim 37, further comprising chlorpromazine.

41. (Previously presented) The solution of claim 40, wherein the concentration of chlorpromazine is about 1-50 micrograms/ml.

42. (Previously presented) The solution of claim 41, wherein the concentration of chlorpromazine is about 2-10 micrograms/ml.

43. (Previously presented) The solution of claim 40 further comprising citrate.

44. (Previously presented) The solution of claim 43, further comprising calcium.

45. (Previously presented) The solution of claim 44, further comprising magnesium.

46. (Previously presented) The solution of claim 45, further comprising adenine.

47. (Previously presented) The solution of claim 46, further comprising glucose.

48. (Previously presented) The solution of claim 47, further comprising acetate.

49. (Previously presented) The solution of claim 48 further comprising phosphate buffer.

50. (Currently amended) The solution of claim ~~36~~ 1, wherein the solution has an osmolality of less than about 350 mOsm.

51. (Currently amended) The solution of claim ~~36~~ 1, wherein the sum of all impermeant species contributes 20-250 mOsm (milliosmolal) to the osmolality of the solution.

Atty. Dkt. No. 074066-0115

52. (Previously presented) A method for the preservation of cells, tissues, or organs under conditions of impaired cell volume homeostasis, comprising:

contacting the cells, tissues, or organs with a solution of claim 1.

53. (Previously presented) A method for the preservation of cells, tissues, or organs under conditions of impaired cell volume homeostasis, comprising:

contacting the cells, tissues, or organs with a solution comprising polyglycerol in an amount effective to preclude or to reverse cell swelling.

54. (Previously presented) The method of claim 53 wherein the contacting is via intravenous or intra-arterial administration.

55. (Previously presented) The method of claim 53 wherein the contacting is in vivo via arterial organ perfusion or retrograde venous perfusion of an organ or vascularized tissue.

56. (Previously presented) The method of claim 53 wherein the contacting is in vitro via arterial organ perfusion or retrograde venous perfusion of an organ or vascularized tissue.

57. (Previously presented) The method of claim 53 wherein the contacting is via the immersion of or bathing of affected cells, tissues, or organs.

58. (Cancelled)

59. (Previously presented) The method of claim 53 wherein the polyglycerol is from $n=2$ to 200 monomer units in length.

60. (Previously presented) The method of claim 53 wherein the polyglycerol is tetraglycerol, hexaglycerol, or decaglycerol.

Atty. Dkt. No. 074066-0115

61. (Previously presented) The method of claim 53 wherein the polyglycerol is at a concentration of from about 20 mOsm to 1,500 mOsm when in contact with the cell, tissue, or organ.

62. (Previously presented) The method of claim 53 wherein the effective amount is an isotonic solution.

63. (Previously presented) The method of claim 53 wherein the effective amount is a hypertonic solution.

64. (Previously presented) A method for the preservation of cells, tissues, or organs under conditions of impaired cell volume homeostasis, comprising:

contacting the cells, tissues, or organs with a solution comprising lactose in an amount effective to preclude or to reverse cell swelling.

65. (Currently amended) The method of claim 64 wherein the lactose is comprises alpha lactose.

66. (Previously presented) The method of claim 64 wherein the lactose is at a concentration from about 11 mM to about 250 mM.

67. (New) The solution of claim 51 wherein the impermeant species are selected from the group consisting of: lactose, polyglycerol, glucose, and citrate.

68. (New) The solution of claim 51 wherein the impermeant species are selected from the group consisting of: lactose, polyglycerol, glucose, and tripotassium citrate.